Edition:
United States

Profile: Perrigo Company PLC (PRGO.K)

PRGO.K on New York Consolidated

91.08USD
28 Jul 2016
Change (% chg)

$-0.26 (-0.28%)
Prev Close
$91.34
Open
$90.89
Day's High
$91.39
Day's Low
$90.48
Volume
1,765,987
Avg. Vol
2,655,796
52-wk High
$198.42
52-wk Low
$84.85

Perrigo Company plc (Perrigo), formerly Perrigo Company Limited, incorporated on June 28, 2013, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's operating segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx), Specialty Sciences and Other segments. The Company manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is a provider of generic extended topical prescription products and it receives royalties from sales of the multiple sclerosis drug, Tysabri. It provides Quality Affordable Healthcare Products across a range of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China.

Consumer Healthcare

The CHC segment is focused on the sale of OTC store brand products in various categories, including analgesics; Cough/cold/allergy/sinus; Gastrointestinal; Infant nutritionals; Smoking cessation; Animal health; VMS, and others, including feminine hygiene, diabetes care, dermatological care, diagnostic products, scar management and other miscellaneous healthcare products. The Company markets in various geographies, including the United States, the United Kingdom and Mexico. Its branded products include the Good Sense, Sergeant's, Sentry, Herron, PetArmor value brands, and the ScarAway brand name.

Branded Consumer Healthcare

The BCH segment develops, manufactures, markets and distributes various European OTC brands in the natural health and VMS, cough, cold and allergy, personal care and derma-therapeutics, lifestyle, smoking cessation and anti-parasite categories. In addition, the segment engages its regulatory, sales and distribution infrastructure to in-license, and sell non-owned brands and generic pharmaceutical products. The BCH segment distributes these products through a network of pharmacies in approximately 40 countries, primarily in Europe. The BCH segment sells products from over 300 brands both on its own and through third parties.

Prescription Pharmaceuticals

The Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs for the United States and the United Kingdom markets. It offers a portfolio of extended topical and specialty products. It also offers an array of topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The portfolio also includes select controlled substances, injectables, hormones, women's health products, oral solid dosage forms and oral liquid formulations. Its development areas include other delivery systems, such as oral liquids, metered dose inhalers, injectables and transdermal products. In addition, the Rx segment offers OTC products through the prescription channel (referred to as ORx, these products are marketed using the Perrigo name). ORx products are OTC products that are available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. It offers numerous ORx products that are reimbursable through various health plans and the United States Medicaid and Medicare programs. It manufactures and distributes a range of generic prescription products under various brand names, including Differin, BenzaClin, Entocort, Evoclin, Duac, Olux, Olux-E, Clobex, Desonate, Tridesilon, D.H.E. 45, Ultravate, Bactroban, Mycostatin, Elimite, Klor-Con, Protopic, Androgel, Depo, Testosterone, Nasacort AQ and Triderm/Kenalog.

Specialty Sciences

The Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug Tysabri (natalizumab). It is entitled to royalty payments from Biogen Idec Inc. (Biogen) based on its Tysabri sales in various indications and geographies.

OTHER

The Company's Other segment consists of active pharmaceutical ingredients (API) business. It develops, manufactures and markets API products, which are used across the world by both generic and branded pharmaceutical companies. Certain of these ingredients are used in its own pharmaceutical products. The manufacturing of API occurs in Israel with some production in India.

The Company competes with LNK International, Inc., PL Developments, International Vitamin Corporation, Dr. Reddy's Labs, Johnson & Johnson, Pfizer, Bayer AG, Nestle S.A., Abbott Nutrition, NBTY, Mead Johnson Nutrition Co., Reckitt Benckiser, Boehringer Ingelheim, Novartis, Allergan plc, Apotex Corp., Glenmark Generics Inc., Impax Laboratories, Inc., Mylan N.V., Prasco, LLC, Sandoz, Sun Pharmaceuticals, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, LLC and Zydus Pharmaceuticals, Inc.

Company Address

Perrigo Company PLC

Treasury Building
Grand Canal Street Lower
DUBLIN     L2 2

Company Web Links